A5063739859- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
- Palliative Care and End-of-Life Issues
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Patient Dignity and Privacy
- Global Cancer Incidence and Screening
- Cancer survivorship and care
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Childhood Cancer Survivors' Quality of Life
- Vitamin D Research Studies
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Colorectal and Anal Carcinomas
- Male Breast Health Studies
- Adipokines, Inflammation, and Metabolic Diseases
- Cancer-related Molecular Pathways
- Inflammatory Biomarkers in Disease Prognosis
- BRCA gene mutations in cancer
University of Genoa
2023-2025
Ospedale Policlinico San Martino
2023-2025
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2020-2023
Vitamin D is rightly recognized as an essential key factor in the regulation of calcium and phosphate homeostasis, affecting primary adequate bone mineralization. In last decades, a more complex wider role vitamin has been postulated demonstrated. Cardiovascular diseases have found to be strongly related levels, especially its deficiency. Pre-clinical studies suggested direct several pathophysiological pathways, such endothelial dysfunction platelet aggregation; moreover, observational data...
The monarchE and NATALEE trials employed different high-risk inclusion criteria. Main objective is to assess prognostic differences based on their Patients with hormone receptor-positive/HER2-negative early breast cancer enrolled in the phase III MIG1, GIM2, GIM3 were categorized as cohort (HRC) low-risk (LRC) according criteria of trials. Subsequently, they further classified three cohortsconcordant LRC (low-risk for both trials), discordant risk (high-risk only one trial), concordant HRC...
Introduction The treatment landscape of non-small cell lung cancer (NSCLC) has seen significant advancements in recent years, marked by a shift toward target agents and immune checkpoint inhibitors (ICIs). However, chemotherapy remains cornerstone treatment, alone or combination. Microtubule-targeting agents, such as taxanes vinca alkaloids, play crucial role clinical practice both early advanced settings NSCLC.
The phase III GIM2 trial showed improved disease-free survival (DFS) and overall (OS) with adjuvant dose-dense (DD) as compared standard-interval (SI) chemotherapy in women node-positive early-stage breast cancer (BC). This exploratory analysis aimed to investigate the benefit of different schedules according body mass index (BMI) this trial.
Background Universal screening of colorectal cancer (CRC) patients for Lynch syndrome (LS) through MisMatch Repair (MMR) testing is recommended. BRAFV600E mutation and/or MLH1 promoter methylation (Reflex Testing, RefT)generally rule out LS in MLH1-deficient (dMLH1) patients. We estimated the impact RefTon genetic counseling (GC) and on diagnostic yield (GT). Methods Overall, 3199 CRC were referred to our center between 2011 2021. Patients until January 2019 (n=2536) underwent universal MMR...
Abstract Objectives To better understand the type of care offered to Italian patients with advanced breast cancer at End-of-Life (EoL), we conducted a retrospective observational study. EoL was defined as period six months before death. Methods One hundred and twenty-one (ABC) treated IRCCS San Martino Policlinic Hospital who died between 2017 2021 were included. Data about patient, disease, treatment characteristics from diagnosis death, along information comorbidities, medications,...
One third of ABC pts is currently represented by women aged over 70. However, this population remains under-represented in clinical trials. Recently, T-DXd revolutionized the treatment HER2 positive ABC, demonstrating its efficacy DESTINY-Breast Its safety profile was manageable and most adverse events (AEs) were gastrointestinal nature. Nevertheless, associated with development interstitial lung disease (ILD) 10-15% pts. Thus, some concerns could raise regarding those outcomes elderly...
BackgroundLung cancer patients diagnosed following emergency admission often present with advanced disease and poor performance status, leading to suboptimal treatment options outcomes. This study aimed investigate the clinical molecular characteristics, initiation, survival outcomes of these patients.MethodsWe retrospectively analyzed data from 124 lung at a single institution. Clinical results analyses for therapeutic purpose, systemic were assessed. Correlations between patients'...
Breast cancer is the most common in women, and luminal breast predominant subtype, characterized by presence of estrogen receptors and/or progesterone tumor cells. Adjuvant endocrine therapy pivotal approach management early cancer. Hence, new therapeutic approaches have been studied during last few years, especially patients with high risk recurrence.Here we provide a summary recent clinical trials evaluating adjuvant treatment hormone-receptors-positive First, main cornerstone related to...
Abstract Background: The long-term results of the Italian randomized phase III GIM2 study showed that, in women with node-positive breast cancer (BC), dose-dense (DD) chemotherapy significantly improved both disease-free survival (DFS) and overall (OS) compared standard-interval (SI) chemotherapy. Obesity has been identified as an independent poor prognostic factor patients BC, a potential negative impact on efficacy toxicity systemic therapies. Nevertheless, specific influence body mass...
Adjuvant endocrine therapy (ET) with exemestane combined LHRH analog (LHRHa) is standard of care for premenopausal women hormone receptor-positive breast cancer. However, LHRHa may not always achieve complete ovarian suppression in these patients. The PREFER-Fertility (NCT02895165) and GIM 23-POSTER (NCT05730647) are prospective, observational studies that enrolled eligible to receive (neo)adjuvant chemotherapy and/or ET. We conducted an exploratory analysis patients achieving suboptimal...
Introduction: We conducted an online survey to investigate oncologists' clinical practices and views on palliative care at the end of life in Italian region Liguria. Methods: The included 29 items divided into three sections: participant characteristics (n=6), hospital resources (n=11), (n=12). Results: Twenty-one 41 medical oncologists invited completed (51%). Although almost all reported presence medicine physicians their hospitals (90%), nearly half (48%) stated that were not responsible...
1024 Background: Estrogen receptors (ER) are considered predictive biomarkers to identify ER+ MBC patients who would likely benefit from endocrine therapies (ET). However, 30 40% of fail achieve a durable response. 18F-FES PET/CT has been shown represent valuable and accurate diagnostic tool determine ER status at the level metastatic sites can be proposed as valid alternative biopsy lesions. In this trial, we evaluated for responsiveness in MBC. Methods: ET-FES is an international,...